Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05302596 · ClinicalTrials.gov registry record · Phase 2
Semaglutide Use in Elderly Obese Patients
A Phase 2 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT05302596 is a Phase 2 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 16 participants.
The verdict
NCT05302596, a Phase 2 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
Interventions
- DRUG Semaglutide Pen Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05302596
The ClinicalTrials.gov registry entry for NCT05302596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide Pen Injector is the first listed.
NCT05302596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05302596 about?
NCT05302596 is a clinical study titled "Semaglutide Use in Elderly Obese Patients". This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA...
What is the current status of trial NCT05302596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-09-01. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT05302596?
The interventions under investigation include: Semaglutide Pen Injector (DRUG).
Who is sponsoring clinical trial NCT05302596?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.